Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy MannKind stock (MNKD)

Buy MannKind stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

MannKind is a biotechnology business based in the US. MannKind shares (MNKD) are listed on the NASDAQ and all prices are listed in US Dollars. MannKind employs 411 staff and has a trailing 12-month revenue of around $224.6 million.

Our top picks for where to buy MannKind stock

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Best for beginners

Go to site
Get up to $10,000 cash
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • No-cost financial planning and automated investing

Our pick for Investing by theme

Go to site
Earn up to $300 on new deposits
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

How to buy MannKind stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – MNKD. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy MannKind stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 6 of 6
Name Product Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Finder Score: 4.4 / 5: ★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
Stocks, Options, Mutual funds, ETFs, Alternatives
Get up to $10,000 cash
Commission-free stocks, ETFs and options, with no options per-contract fees. Plus, a no-cost robo-advisor and complimentary access to certified financial planners (CFPs).
Not rated yet
Stocks, ETFs
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
Cash App
Finder Score: 3 / 5: ★★★★★
Cash App
Stocks, ETFs, Cryptocurrency
Buy and sell over 1,800 stocks and ETFs commission-free and for as little as $1.
Finder Score: 4.3 / 5: ★★★★★
Stocks, Options, ETFs
Up to 8.10%
Choose a 1.5% match or up to 15 free fractional shares
No commission stock, ETF and options trades, with $0 equity options contract fees, low margin rates and advanced trading tools.
Finder Score: 4.2 / 5: ★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

MannKind stock price (NASDAQ: MNKD)

Use our graph to track the performance of MNKD stocks over time.

MannKind shares at a glance

Information last updated 2024-07-14.
Latest market close$5.83
52-week range$3.17 - $5.77
50-day moving average $4.81
200-day moving average $4.15
Wall St. target price$7.08
PE ratio 142.5
Dividend yield N/A (0%)
Earnings per share (TTM) $0.04

Is it a good time to buy MannKind stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

MannKind price performance over time

Historical closes compared with the close of $5.83 from 2024-07-15

1 week (2024-07-10) 5.42%
1 month (2024-06-17) 22.74%
3 months (2024-04-17) 42.20%
6 months (2024-01-17) 77.74%
1 year (2023-07-17) 34.02%
2 years (2022-07-15) 47.22%
3 years (2021-07-16) 31.90%
5 years (2019-07-17) 460.58%

Is MannKind stock undervalued or overvalued?

Valuing MannKind stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of MannKind's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

MannKind's P/E ratio

MannKind's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 143x. In other words, MannKind shares trade at around 143x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

MannKind's EBITDA

MannKind's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $35.8 million.

The EBITDA is a measure of a MannKind's overall financial performance and is widely used to measure a its profitability.

MannKind financials

Revenue TTM $224.6 million
Operating margin TTM 23.13%
Gross profit TTM $42.3 million
Return on assets TTM 4.97%
Return on equity TTM 0%
Profit margin 3.78%
Book value $-0.85
Market Capitalization $1.6 billion

TTM: trailing 12 months

MannKind share dividends

We're not expecting MannKind to pay a dividend over the next 12 months.

Have MannKind's shares ever split?

MannKind's shares were split on a 1:5 basis on 2 March 2017. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your MannKind shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for MannKind shares which in turn could have impacted MannKind's share price.

MannKind share price volatility

Over the last 12 months, MannKind's shares have ranged in value from as little as $3.17 up to $5.77. A popular way to gauge a stock's volatility is its "beta".

MNKD.US volatility(beta: 1.32)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MannKind's is 1.318. This would suggest that MannKind's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

MannKind overview

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S. A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd.

Frequently asked questions

What percentage of MannKind is owned by insiders or institutions?
Currently 2.036% of MannKind shares are held by insiders and 50.132% by institutions.
How many people work for MannKind?
Latest data suggests 411 work at MannKind.
When does the fiscal year end for MannKind?
MannKind's fiscal year ends in December.
Where is MannKind based?
MannKind's address is: 1 Casper Street, Danbury, CT, United States, 06810
What is MannKind's ISIN number?
MannKind's international securities identification number is: US56400P7069
What is MannKind's CUSIP number?
MannKind's Committee on Uniform Securities Identification Procedures number is: 56400P201

More guides on Finder

Ask a Question provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site